AI/ML for Genomic therapies
Whitelab Genomics (Paris) uses AI to speed up pre-clinical discovery and development for gene therapies. They harmonize and ingest multiple multi-omics data sources, then analyze with AI to discover targets and design payloads and vectors for gene therapy.
The company is headquartered in Paris, France.View website
Why we invested in WhiteLab Genomics
Gene therapy, although in its infancy, is an important therapeutic modality of the future. In-silico approaches will be increasingly used at all stages of drug discovery and development for all modalities, and this is expected to radically impact the time taken and the success of new drug development. This investment may be seen as complementary to our investment in Mekonos, and will allow us to further learn about gene therapy and deepen our understanding of in-silico approaches to drug development.
Discover how we can help you bring your ambition to life
September 13, 2022
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence